The stock of OvaScience Inc (NASDAQ:OVAS) is a huge mover today! About 197,475 shares traded hands. OvaScience Inc (NASDAQ:OVAS) has declined 8.23% since March 8, 2016 and is downtrending. It has underperformed by 17.55% the S&P500.
The move comes after 6 months negative chart setup for the $248.26M company. It was reported on Oct, 11 by Barchart.com. We have $6.14 PT which if reached, will make NASDAQ:OVAS worth $24.83M less.
Analysts await OvaScience Inc (NASDAQ:OVAS) to report earnings on November, 3. They expect $-0.62 earnings per share, up 6.06% or $0.04 from last year’s $-0.66 per share. After $-0.62 actual earnings per share reported by OvaScience Inc for the previous quarter, Wall Street now forecasts 0.00% EPS growth.
OvaScience Inc (NASDAQ:OVAS) Ratings Coverage
Out of 5 analysts covering OvaScience (NASDAQ:OVAS), 1 rate it a “Buy”, 1 “Sell”, while 3 “Hold”. This means 20% are positive. OvaScience has been the topic of 9 analyst reports since August 11, 2015 according to StockzIntelligence Inc. On Tuesday, September 29 the stock rating was downgraded by JMP Securities to “Mkt Perform”. On Monday, November 9 the stock rating was downgraded by Leerink Swann to “Market Perform”. On Thursday, January 21 the stock rating was initiated by Credit Suisse with “Underperform”. On Wednesday, September 30 the stock rating was maintained by Oppenheimer with “Outperform”. On Tuesday, August 11 the stock rating was maintained by Wedbush with “Outperform”. The stock of OvaScience Inc (NASDAQ:OVAS) has “Outperform” rating given on Wednesday, October 21 by Oppenheimer. Leerink Swann maintained OvaScience Inc (NASDAQ:OVAS) rating on Friday, August 14. Leerink Swann has “Outperform” rating and $48 price target. The firm has “Perform” rating by Oppenheimer given on Monday, January 25.
According to Zacks Investment Research, “OvaScience, Inc. is a life science company focused on the discovery, development and commercialization of new treatments for infertility. Its product includes Augment for the treatment of infertility and Ova Ture used in the creation of mature fertilizable eggs. Ova Science, Inc. is headquartered in Cambridge, Massachusetts.”
Insitutional Activity: The institutional sentiment increased to 3.37 in 2016 Q2. Its up 2.50, from 0.87 in 2016Q1. The ratio improved, as 7 funds sold all OvaScience Inc shares owned while 12 reduced positions. 17 funds bought stakes while 47 increased positions. They now own 51.93 million shares or 132.78% more from 22.31 million shares in 2016Q1.
Portolan Mgmt Limited reported 400,510 shares or 0.3% of all its holdings. Morgan Stanley last reported 23,925 shares in the company. Employees Retirement System Of Texas last reported 55,000 shares in the company. Gmt reported 447,245 shares or 0.06% of all its holdings. Bank & Trust Of Montreal Can holds 0% or 908 shares in its portfolio. Blackrock holds 5,792 shares or 0% of its portfolio. State Board Of Administration Of Florida Retirement has 12,048 shares for 0% of their US portfolio. Moreover, Manufacturers Life Ins The has 0% invested in OvaScience Inc (NASDAQ:OVAS) for 23,773 shares. Bbt Cap Mgmt Limited Liability Company last reported 253,680 shares in the company. Schwab Charles Invest has 61,601 shares for 0% of their US portfolio. Susquehanna Group Llp last reported 0% of its portfolio in the stock. Moreover, Marshall Wace Llp has 0.01% invested in OvaScience Inc (NASDAQ:OVAS) for 247,179 shares. California State Teachers Retirement Sys accumulated 65,828 shares or 0% of the stock. Invesco Ltd last reported 0% of its portfolio in the stock. Geode Mgmt Limited Com holds 0% of its portfolio in OvaScience Inc (NASDAQ:OVAS) for 199,106 shares.
Insider Transactions: Since May 10, 2016, the stock had 10 insider buys, and 0 selling transactions for $1.76 million net activity. ALDRICH RICHARD bought $153,628 worth of OvaScience Inc (NASDAQ:OVAS) on Tuesday, May 10. Dipp Michelle bought $157,200 worth of stock or 20,000 shares. Shares for $22,847 were bought by CHAPMAN PAUL W.D. on Tuesday, May 10.
OVAS Company Profile
OvaScience, Inc., incorporated on April 5, 2011, is a global fertility company. The Firm is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue. The Company’s AUGMENT treatment is specifically designed to improve egg health by supplementing a mitochondrial deficiency. With the AUGMENT treatment, energy-producing mitochondria from a patient’s own EggPC cells are added to the patient’s mature eggs during the in vitro fertilization (IVF) process to supplement the existing mitochondria.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.